{"organizations": [], "uuid": "b4126d8c7ae3a9db8daec96b53df77b3ece2d7cb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-approves-janssen-pharmaceutica/brief-fda-approves-janssen-pharmaceuticals-erleada-for-a-certain-type-of-prostate-cancer-idUSFWN1Q41DX", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves Janssen Pharmaceutical's Erleada For A Certain Type Of Prostate Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-14T22:49:00.000+02:00", "replies_count": 0, "uuid": "b4126d8c7ae3a9db8daec96b53df77b3ece2d7cb"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-approves-janssen-pharmaceutica/brief-fda-approves-janssen-pharmaceuticals-erleada-for-a-certain-type-of-prostate-cancer-idUSFWN1Q41DX", "ord_in_thread": 0, "title": "BRIEF-FDA Approves Janssen Pharmaceutical's Erleada For A Certain Type Of Prostate Cancer", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "janssen pharmaceutical", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " FDA Approves Janssen Pharmaceutical's Erleada For A Certain Type Of Prostate Cancer Reuters Staff 1 Min Read Feb 14 (Reuters) - The U.S. Food and Drug Administration: * SAYS APPROVED JANSSEN PHARMACEUTICAL‘S ERLEADA FOR A CERTAIN TYPE OF PROSTATE CANCER USING NOVEL CLINICAL TRIAL ENDPOINT‍​  ", "external_links": [], "published": "2018-02-14T22:49:00.000+02:00", "crawled": "2018-02-14T23:06:11.014+02:00", "highlightTitle": ""}